

Table. Number (%) of Patients Taking Concomitant Lamotrigine or Carbamazepine at Baseline, Those Who Remained or Discontinued Cenobamate, and Dose Adjustments and Timing by ASM at Time of Post-hoc Analysis

	Concomitant Lamotrigine		Concomitant Carbamazepine	
At baseline, n (%)^a	69 (27.7)		22 (8.8)	
Remained on cenobamate, n (%)^b	52 (75.4)		14 (63.6)	
Discontinued cenobamate, n (%)^b	17 (24.6)		8 (36.4)	
Mean cenobamate dose at start of dose reductions to concomitant ASMs, mg	210.7		182.5	
	Mean starting dose	Mean dose after reduction	Mean starting dose	Mean dose after reduction
Mean concomitant ASM dose in patients who remained on cenobamate, mg	499.5	384.1	921.4	478.6
Mean concomitant ASM dose in patients who discontinued cenobamate, mg	455.9	366.2	914.3	600.0

^aPercentages calculated from a total 249 patients.

^bPercentages calculated from total number of patients taking the specific concomitant drug at baseline.

ASM, antiseizure medication.